Early off-label treatment during pandemics? A dilemma

Jan A. Roth; Tala Ballouz; Roger D. Kouyos; Manuel Battegay

doi:10.4414/smw.2020.20281

Viewpoint

Vol. 150 No. 1920 (2020)

Early off-label treatment during pandemics? A dilemma

Jan A. Roth
Tala Ballouz
Roger D. Kouyos
Manuel Battegay

DOI: https://doi.org/10.4414/smw.2020.20281
Cite this as:: Swiss Med Wkly. 2020;150:w20281
Published: 11.05.2020

References

Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282
Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457
Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448
Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006

Publication image

How to Cite

1.

Roth JA, Ballouz T, Kouyos RD, Battegay M. Early off-label treatment during pandemics? A dilemma. Swiss Med Wkly [Internet]. 2020 May 11 [cited 2024 Oct. 16];150(1920):w20281. Available from: https://smw.ch/index.php/smw/article/view/2787

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Anna Gamell, Emili Letang, Boniface Jullu, Geoffrey Mwaigomole, Angelo Nyamtema, Christoph Hatz, Manuel Battegay, Marcel Tanner, Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change , Swiss Medical Weekly: Vol. 143 No. 1112 (2013)
Peter Hengstler, Edouard Battegay, Jacques Cornuz, Heiner Bucher, Manuel Battegay, Evidence for prevention and screening: recommendations in adults , Swiss Medical Weekly: Vol. 132 No. 2728 (2002)
Kathrin Bausch, Jan A. Roth, Hans-H. Seifert, Andreas F. Widmer, Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate , Swiss Medical Weekly: Vol. 148 No. 0708 (2018)
Manuel Battegay, Luigia Elzi, Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities , Swiss Medical Weekly: Vol. 139 No. 3940 (2009)

<< < 1 2 3

[1] Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477

[2] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282

[3] Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457

[4] Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448

[5] Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006